Reducing sedentary behavior in patients with chronic kidney disease and obesity
Sit Less, Interact and Move More (SLIMM) 2 Study
PHASE2 · University of Utah · NCT05173714
This study is testing if a combination of guided exercise and a diabetes medication can help people with chronic kidney disease and obesity sit less and be more active.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 156 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | University of Utah (other) |
| Locations | 2 sites (Stanford, California and 1 other locations) |
| Trial ID | NCT05173714 on ClinicalTrials.gov |
What this trial studies
The Sit Less, Interact and Move More (SLIMM) 2 study aims to address the negative health impacts of prolonged sitting in individuals with chronic kidney disease and obesity. This interventional study will evaluate the effectiveness of guided resistance training combined with semaglutide, a medication approved for diabetes and weight loss, to enhance adherence to a program designed to reduce sedentary behavior. Participants will be monitored for changes in physical activity levels and overall health outcomes. The study is being conducted at the University of Utah and Stanford University.
Who should consider this trial
Good fit: Ideal candidates include individuals with chronic kidney disease who have an eGFR between 20 and 60 mL/min/1.73m² and are able to perform resistance training.
Not a fit: Patients with type 1 diabetes, certain gastrointestinal conditions, or those who are expected to start dialysis or kidney transplantation within 6 months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved physical function and reduced health risks for patients with chronic kidney disease and obesity.
How similar studies have performed: Previous studies have shown that interventions targeting sedentary behavior can be effective, but this specific approach combining resistance training and semaglutide is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2 * Able to perform resistance training * Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop Exclusion Criteria: * Type 1 Diabetes * History of gastroparesis or paralytic ileus * At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer * Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma. * Previous bariatric surgery * Medical condition likely to limit survival to less than 1 year * Anticipated start of dialysis or kidney transplantation within 6 months * Any factors judged by the investigator or study team to likely limit adherence to interventions * Vulnerable populations- pregnant or incarcerated * Enrolled in interventional trials using drugs or devices * Not able to undergo informed consent * Recent hospitalizations or major interventional procedures done within the past 60 days * Known or suspected hypersensitivity to tegaderm * Use of any GLP-1 receptor agonist within 30 days prior to screening * Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure * Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system) * Presence of metastatic cancer * Current use of mobility aid(s) * Living in the same household of a participant already enrolled in the study
Where this trial is running
Stanford, California and 1 other locations
- Stanford University — Stanford, California, United States (RECRUITING)
- University of Utah — Salt Lake City, Utah, United States (RECRUITING)
Study contacts
- Principal investigator: Srinivasan Beddhu, M.D. — University of Utah
- Study coordinator: Amara Sarwal, M.D.
- Email: Amara.Sarwal@hsc.utah.edu
- Phone: 801-585-9815
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Kidney Diseases, Obesity